Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR3 dec exp FGFR3 wild-type HRAS G12V |
| Therapy | Fexagratinib |
| Indication/Tumor Type | transitional cell carcinoma |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 dec exp FGFR3 wild-type HRAS G12V | transitional cell carcinoma | resistant | Fexagratinib | Preclinical | Actionable | In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to Fexagratinib (AZD4547) in culture (PMID: 22869148). | 22869148 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (22869148) | Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. | Full reference... |